Creative Biolabs Gets Ready to Power Antibody and Peptide Discovery Targeting Bacteria Disease


(Spin Digit Editorial):- New York City, New York Jul 21, 2021 ( – Antibiotic resistance occurs when bacteria change in response to the use of antibiotics, which is now one of the biggest threats to global health, food security, and development. Research on new strategies fighting against bacteria is in urgent need to prevent and control the spread of antibiotic resistance. Antibody and antimicrobial peptide (AMP) are promising methods to resist bacteria diseases, and thus to solve this problem.

With years of efforts in the fields of antibody and peptide development, Creative Biolabs now provides a whole pipeline of services on antibody and peptide discovery for bacterial disease, covering a broad range of targets, such as multi-drug resistant (MDR) bacteria, Gram-positive bacteria, and Gram-negative bacteria, Mycoplasma and Chlamydia.

For MDR bacteria, the expert team at Creative Biolabs has studied specific targets for antibodies against these bacteria, such as lipopolysaccharide (LPS), capsular polysaccharide (CPS), conserved exopolysaccharides, pilus formation proteins, extracellular vesicle components, and other proteins. Extensive experience is accumulated in tailoring strategies to discover antibodies and peptides targeting Streptococcus, Pseudomonas, Enterococcus, Staphylococcus, Mycobacterium, and other MDR bacteria.

More on Spindigit:

For Gram-positive bacteria, many antibodies specific for lipoteichoic acid (LTA) have been developed for bacteria detection. Creative Biolabs has developed several strategies for antibody and AMP development against LTA and diverse surface proteins of Gram-positive bacteria, covering Listeria, Bacillus, Streptococcus, Enterococcus, and Staphylococcus.

For Gram-negative bacteria, AMPs can act as immune effectors and evolve different mechanisms to inactivate bacteria, and antibodies can bind outer membrane or cell surface structures, thereby preventing adhesion, disrupting specific virulence functions, or targeting bacteria for phagocytosis. Creative Biolabs offers discovery services of antibodies and peptides targeting Helicobacter, Escherichia, Salmonella, Campylobacter, Haemophilus, Pseudomonas, etc.

For mycoplasma and chlamydia, Creative Biolabs has developed an advanced anti-bacteria biomolecular discovery system to provide various biomolecular identification services for different purposes, including but not limited to antibody development, peptide identification, immunogenic proteins epitope mappings, and epitope identification.

“We have established a high-throughput AntInfect Platform for biomolecular development against infectives. What’s more, to support related research, our team has launched a comprehensive list of premade peptide libraries for antimicrobial peptide discovery,” introduced by a senior scientist at Creative Biolabs, “we are skillful in peptide array design and scalable, reproducible photolithographic synthesis of high-quality peptide arrays.”

Further information can be found on


About Creative Biolabs

As a leading custom service provider in antibody development and engineering, Creative Biolabs has established cutting-edge technology to support functional biomolecules development for infectious diseases. The service portfolio is comprised of anti-infective biomolecules discovery, CRISPR screening, siRNA screening, and small molecule drug discovery.

Source :Creative Biolabs

This article was originally published by IssueWire. Read the original article here.